voclosporin + Ciclosporin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis
Conditions
Psoriasis
Trial Timeline
Dec 1, 2006 → Dec 1, 2008
NCT ID
NCT00408187About voclosporin + Ciclosporin + Placebo
voclosporin + Ciclosporin + Placebo is a phase 3 stage product being developed by Aurinia Pharmaceuticals for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00408187. Target conditions include Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00408187 | Phase 3 | Completed |
Competing Products
20 competing products in Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous | Eli Lilly | Phase 2 | 52 |
| Ixekizumab | Eli Lilly | Phase 3 | 77 |
| 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Baricitinib | Eli Lilly | Phase 2 | 52 |
| CT-P43 + Stelara | Celltrion | Phase 3 | 77 |
| CT-P17 + EU-approved Humira | Celltrion | Phase 3 | 77 |
| CT-P55 + EU-approved Cosentyx | Celltrion | Phase 3 | 77 |
| AMG 139 | AstraZeneca | Phase 1 | 33 |
| alefacept + polyvalent pneumococcal vaccine | Astellas Pharma | Approved | 85 |
| alefacept | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Phase 3 | 77 |
| peficitinib + Placebo | Astellas Pharma | Phase 2 | 52 |
| Alefacept | Astellas Pharma | Phase 3 | 77 |
| Amevive exposure | Astellas Pharma | Pre-clinical | 23 |
| alefacept + placebo | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Approved | 85 |
| ASKP1240 + Placebo | Astellas Pharma | Phase 2 | 52 |